DelveInsight has launched a new report on “Attention-deficit/hyperactivity disorder (ADHD) Market Insights, Epidemiology, and Market Forecast-2030”.
DelveInsight’s “Attention-deficit/hyperactivity disorder (ADHD) Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Attention-deficit/hyperactivity disorder (ADHD), historical and forecasted epidemiology as well as the Attention-deficit/hyperactivity disorder (ADHD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the Key facts:
- The total market size for Attention Deficit Hyperactivity Disorder was USD 15,094 Million in 2016
- The US has the highest number of cases, followed by Japan and other European countries.
- France had the highest diagnosed prevalent population of ADHD with 2,376,591 cases,
- Japan had 3,122,705 diagnosed prevalent cases of ADHD.
Request for Free Sample Report: https://www.delveinsight.com/sample-request/attention-deficit-hyperactivity-disorder-adhd-market
Report Highlights:
- The report covers the descriptive overview of Attention-deficit/hyperactivity disorder (ADHD), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the Attention-deficit/hyperactivity disorder (ADHD) epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Attention-deficit/hyperactivity disorder (ADHD) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of Attention-deficit/hyperactivity disorder (ADHD) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Attention-deficit/hyperactivity disorder (ADHD) market
Attention-deficit/hyperactivity disorder (ADHD) is a brain disorder marked by an ongoing pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development. ADHD is a group of behaviors and is also called as attention deficit disorder (ADD). ADHD is a behavioral disorder that includes symptoms such as inattentiveness, hyperactivity, and impulsiveness.
Symptoms of ADHD tend to be noticed at an early age and may become more noticeable when a child’s circumstances change, such as when they start school. Most cases are diagnosed when children are 6 to 12 years old. The symptoms of ADHD usually improve with age, but many adults who were diagnosed with the condition at a young age continue to experience problems. People with ADHD may also have additional problems, such as sleep and anxiety disorders.
According to a study conducted by Guifeng et al. titled “Twenty-Year Trends in Diagnosed Attention-Deficit/Hyperactivity Disorder among US Children and Adolescents, 1997–2016,” published in 2018, estimated the prevalence of diagnosed attention-deficit/hyperactivity disorder increased significantly between 1997 and 2016. It has also been observed that the prevalence in children varied between 7.7% and 13.5%.
Subtype-specific diagnosed prevalence of ADHD is divided into various types such as Inattentive; Hyperactive/impulsive; combined. As per DelveInsight estimates, the diagnosed prevalence of combined type of ADHD was found to be highest in the United States.
Request for Free Sample Report: https://www.delveinsight.com/sample-request/attention-deficit-hyperactivity-disorder-adhd-market
- Shire
- Hisamitsu Pharmaceutical Co
- Neos Therapeutics
- Rhodes Pharmaceuticals
- Tris Pharma
- Highland Therapeutics
- Supernus Pharmaceuticals
- Aevi Genomic Medicine
- Sumitomo Dainippon Pharma
- Kempharm
- NLS Pharma
- RespireRx Pharmaceuticals
- Ostuka Pharmaceuticals
And many others
Drugs covered
- Vyvanse
- Mydayis
- Daytrana
- Adzenys
- Cotempla XR-ODT
- Aptensio XR
- Dyanavel XR
- Jornay
- SPN-812
- SPN-810
- AEVI-001/ AEVI-004
- Dasotraline (SEP-225289)
- KP415
- NLS-1
- CX717
- Centanafadine
And many others
Request for Free Sample Report: https://www.delveinsight.com/sample-request/attention-deficit-hyperactivity-disorder-adhd-market
Table of Contents:
1. Key Insights
2. Executive Summary of Attention-deficit/hyperactivity disorder (ADHD)
3. Competitive Intelligence Analysis for Attention-deficit/hyperactivity disorder (ADHD)
4. Attention-deficit/hyperactivity disorder (ADHD): Market Overview at a Glance
5. Attention-deficit/hyperactivity disorder (ADHD): Disease Background and Overview
6. Patient Journey
7. Attention-deficit/hyperactivity disorder (ADHD) Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Attention-deficit/hyperactivity disorder (ADHD) Treatment
11. Marketed Products
12. Emerging Therapies
13. Attention-deficit/hyperactivity disorder (ADHD): Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Attention-deficit/hyperactivity disorder (ADHD)
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Request for Detailed TOC: https://www.delveinsight.com/sample-request/attention-deficit-hyperactivity-disorder-adhd-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/